AbbVie Contract Manufacturing AbbVie Contract Manufacturing

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu
    [{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Announces Resubmission of Biologics License Application to USFDA for Ryplazim\u00ae (plasminogen)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Provides Update on Progress on BLA for Ryplazim\u00ae(plasminogen)","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"September 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Announces Upcoming Presentations for Ryplazim\u00ae (plasminogen) at the 62nd ASH Annual Meeting and Exposition","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim\u00ae(Plasminogen) BLA","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"November 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"$22.0 million","upfrontCash":"Undisclosed","newsHeadline":"Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Prometic Biotherapeutic","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Approved","country":"","productType":"Large molecule","productStatus":"Approved","date":"June 2021","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Approved"},{"orgOrder":0,"company":"Liminal BioSciences","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Liminal BioSciences Presents Two Case Histories on Investigational Intravenous Plasminogen (Human) Replacement Therapy at ASH Conference","therapeuticArea":"Genetic Disease","highestDevelopmentStatus":"Phase III","country":"CANADA","productType":"Large molecule","productStatus":"Approved","date":"December 2020","url1":"","url2":"","graph1":"Genetic Disease","graph2":"Phase III"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kedrion Biopharma Grows in North America As it Completes Acquisition of Prometic","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"October 2021","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved"},{"orgOrder":0,"company":"Kedrion","sponsor":"Kedrion","pharmaFlowCategory":"D","amount":"$17.0 million","upfrontCash":"Undisclosed","newsHeadline":"Kedrion enters into Agreement with Liminal BioSciences","therapeuticArea":"Rare Diseases and Disorders","highestDevelopmentStatus":"Approved","country":"U.S.A","productType":"Large molecule","productStatus":"Approved","date":"May 2021","url1":"","url2":"","graph1":"Rare Diseases and Disorders","graph2":"Approved"}]

    Find Clinical Drug Pipeline Developments & Deals for Plasminogen

    Menu

    Plasminogen

    DEVELOPMENTS

    DOSSIERs // Finished Dosage Forms

    DIGITAL CONTENT

    PharmaCompass
    Loading...

    All Data

    Previous
    Next
    Filters Filter
    ×
    FILTER:
    filter Company
      filter Sponsor
        filter Country
          filter Therapeutic Area
            filter Study Phase

              Active Filter(s):

              refreshFilters
              refreshReset Filter
              refresh Reset Filter
              price-trend All Developments

              Companies By Therapeutic Area

              Development Status

              Kedrion

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kedrion Biopharma Grows in North America As it Completes Acquisition of Prometic

              Details:

              With the acquisition of Prometic, Kedrion has finalized a series of transactions with the announcement that it was acquiring the plasma purification plant at Laval in Québec, and the license to distribute the new product called Ryplazim in the United States.

              Lead Product(s): Plasminogen

              Therapeutic Area: Rare Diseases and Disorders Product Name: Ryplazim

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kedrion

              Deal Size: $17.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition October 18, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Prometic Biotherapeutic

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Country
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Liminal BioSciences Announces Signature of a Share Purchase Agreement for sale of Remaining Plasma-derived Business with Kedrion

              Details:

              This acquisition would include the Ryplazim® (plasminogen, human-tvmh) (“Ryplazim®”) business operated through its subsidiaries, Prometic Bioproduction Inc., the Company’s plasma-derived therapeutics manufacturing facility (“PBP”), and Prometic Biotherapeutics Inc.

              Lead Product(s): Plasminogen

              Therapeutic Area: Genetic Disease Product Name: Ryplazim

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kedrion

              Deal Size: $17.0 million Upfront Cash: Undisclosed

              Deal Type: Agreement June 23, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Liminal BioSciences

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Liminal BioSciences Announces Closing of Divestiture of Plasma Collection Centers and Enters into Option Agreement with Kedrion

              Details:

              Kedrion will enter into an option agreement with Liminal BioSciences to acquire the remainder of the company’s plasma-derived business, as well as Plasminogen business operated through its subsidiaries including Prometic Biotherapeutics which holds the BLA for Ryplazim.

              Lead Product(s): Plasminogen

              Therapeutic Area: Genetic Disease Product Name: Ryplazim

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kedrion

              Deal Size: $22.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition May 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Kedrion

              Contact Supplier
              • Deals
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag U.S.A
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Kedrion enters into Agreement with Liminal BioSciences

              Details:

              According to terms and conditions, the Option would grant Kedrion the right to acquire all of the shares of PBP and PBT and would entitle Liminal BioSciences to receive up to seventy percent of the net proceeds, if granted, associated with a potential FDA approval of Ryplazim.

              Lead Product(s): Plasminogen

              Therapeutic Area: Rare Diseases and Disorders Product Name: Ryplazim

              Highest Development Status: Approved Product Type: Large molecule

              Partner/Sponsor/Collaborator: Kedrion

              Deal Size: $17.0 million Upfront Cash: Undisclosed

              Deal Type: Acquisition May 17, 2021

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Liminal BioSciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Liminal BioSciences Presents Two Case Histories on Investigational Intravenous Plasminogen (Human) Replacement Therapy at ASH Conference

              Details:

              Two posters were presented that highlighted individual case histories of patients with C-PLGD treated with the investigational intravenous Ryplazim® (plasminogen) in compassionate use and expanded access cases.

              Lead Product(s): Plasminogen

              Therapeutic Area: Genetic Disease Product Name: Ryplazim

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable December 07, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Liminal BioSciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Liminal BioSciences Announces FDA Extension of Review Period for Ryplazim®(Plasminogen) BLA

              Details:

              The BLA resubmission for Ryplazim® was supported by data from a Phase 2/3 clinical trial, which evaluated 15 patients, both pediatric and adults, with C-PLGD over 48 weeks of therapy with Ryplazim®.

              Lead Product(s): Plasminogen

              Therapeutic Area: Genetic Disease Product Name: Ryplazim

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Liminal BioSciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Liminal BioSciences Announces Upcoming Presentations for Ryplazim® (plasminogen) at the 62nd ASH Annual Meeting and Exposition

              Details:

              Two abstracts related to the Company’s clinical development activities of Ryplazim® for the treatment of Congenital Plasminogen Deficiency will be presented at the 62nd American Society of Hematology Annual Meeting and Exposition scheduled to take place in a virtual format.

              Lead Product(s): Plasminogen

              Therapeutic Area: Genetic Disease Product Name: Ryplazim

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable November 05, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Liminal BioSciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Liminal BioSciences Provides Update on Progress on BLA for Ryplazim®(plasminogen)

              Details:

              The BLA resubmission for Ryplazim® is supported by data from a Phase 2/3 clinical study which evaluated 15 patients, both pediatric and adults, with congenital plasminogen deficiency over 48 weeks of therapy with Ryplazim®.

              Lead Product(s): Plasminogen

              Therapeutic Area: Genetic Disease Product Name: Ryplazim

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 21, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity

              Liminal BioSciences

              Contact Supplier
              • Development Update
              Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE
              Post an Enquiry Post an Enquiry
              Flag Canada
              Virtual Booth Virtual Booth
              Digital Content Digital Content

              Liminal BioSciences Announces Resubmission of Biologics License Application to USFDA for Ryplazim® (plasminogen)

              Details:

              In a pivotal phase 2/3 clinical trial for the treatment of C-PLGD, all of the patients treated with Ryplazim® achieved at least the targeted increase from baseline in their individual trough plasminogen activity levels through 12 weeks of therapy.

              Lead Product(s): Plasminogen

              Therapeutic Area: Genetic Disease Product Name: Ryplazim

              Highest Development Status: Phase III Product Type: Large molecule

              Partner/Sponsor/Collaborator: Not Applicable

              Deal Size: Not Applicable Upfront Cash: Not Applicable

              Deal Type: Not Applicable September 08, 2020

              ASK
              US
              PHARMACOMPASS
              Upload
              your Pipeline Activity
              Biopharma Group offers CDMO services with expertise in contract R&D for dried products & liquid formulations.
              Rochem, your partner in developing, sourcing, and supplying pharmaceutical & animal health ingredients of Chinese origin.
              Post Enquiry
              POST ENQUIRY